Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 5/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.45 |
| ▸ | ERBB3 | P21860 | 4/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690643 | 0.89 | CDK1 (0.49) | NPC1MAP4K4CDK1EGFRSRC | |
| SCHEMBL691488 | 0.88 | CDK1 (0.48) | NPC1MAP4K4CDK1EGFRSRC | |
| SCHEMBL18805591 | 0.84 | ATR (0.45) | NPC1MAP4K4CDK1EGFRSRC | |
| SCHEMBL29400652 | 0.84 | ATR (0.45) | NPC1MAP4K4CDK1EGFRSRC | |
| SCHEMBL4108813 | 0.84 | NPC1 (0.56) | NPC1EGFRERBB3MKNK1MEN1 | |
| SCHEMBL4301854 | 0.82 | MAP4K4 (0.56) | MAP4K4CDK1EGFRSRCCYP17A1 | |
| SCHEMBL17265777 | 0.81 | EGFR (0.42) | NPC1MAP4K4CDK1EGFRSRC | |
| SCHEMBL5451118 | 0.81 | MAP2K7 (0.51) | MAP4K4CDK1CYP17A1MAPKAPK2 | |
| SCHEMBL1243788 | 0.80 | NPC1 (0.57) | NPC1EGFRERBB3MKNK1MEN1 | |
| SCHEMBL4665750 | 0.80 | CYP1A2 (0.58) | MAP4K4EGFRERBB3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
| EP-1709007-A1 | N-4-(6-(HETEO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS | Altana Pharma AG (DE) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070900-A1 | N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | NPC1 3643/4885MAP4K4 23/4885CDK1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.